Myriad Publications  |   Documents and Forms  |   Registries

The myRisk Hereditary Cancer Test
helps you make the decisions that matter most

Myriad myRisk® Hereditary Cancer tests for mutations in multiple genes associated with an increased risk for 8 different cancers. myRisk testing is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status and personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing.

Learn More

Genes Icon

Affordable

3 out of 4 patients pay $0

Genes Icon

Fast

Average turnaround time is 7-14 days

Genes Icon

Easy

We make genetic testing simple for your patients and your practice

myRisk is Identifying Risk for Your Patients

myRisk Hereditary Cancer Panel

Multi-gene panel determines hereditary cancer risk associated with 8 cancer sites:

  • Breast
  • Ovarian
  • Colorectal
  • Endometrial
  • Melanoma
  • Pancreatic
  • Gastric
  • Prostate
riskScore® Breast Cancer Prediction Tool

Clinically validated to predict both a woman’s 5-year, and remaining lifetime risk of developing breast cancer using genetic markers and clinical risk factors:

  • More than 80 well-studied genetic markers linked to breast cancer risk
  • Tyrer-Cuzick factors
myRisk Management Tool (MMT)

Test results are accompanied with the MMT which summarizes professional society guidelines for medical management based on patient’s individual results. Interventions are proven to reduce future risk of cancer

Learn More

Genes Icon

The riskScore precision medicine tool is clinically validated to predict a woman’s risk of developing breast cancer using clinical risk factors and genetic-markers. It provides women with their remaining lifetime and 5-year risk for developing breast cancer.

Genes Icon

The myRisk test report provides recommendations for managing patients with both positive AND negative genetic results. Every report includes the myRisk Genetic Result and a personalized myRisk Management Tool based on professional medical society guidelines

Genes Icon

In the largest validation study of its kind, Myriad estimated analytical sensitivity of greater than 99.92% with 100% concordance on NGS/Sanger parallel sequencing in all genes in the Myriad myRisk panel and 100% concordance on large rearrangement validation.

Myriad is Your Trusted Advisor

  • 27+ years of experience in hereditary cancer testing
  • Analytically validated high-throughput sequencing
  • Industry leading variant classification program
  • Lifetime commitment to variant classification & result updates

Commitment to Providing Broad Patient Access

  • Myriad works directly with patients to provide up front clarity and resolve questions about cost (cost estimator coming soon)
  • Affordability options personalized to patients’ unique needs
  • 97% of private insurance have coverage for testing
  • Pre-test counseling services to educate patients on HC testing (post-test coming soon)
  • 90% of patients have or will qualify for a payment of $100 or less

Variant Classification

Myriad is the unquestioned industry leader in variant classification and reclassification. myVision™ is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families.

10,071

Variants Classified in 2016

529

Variants Re-classified in 2016

23,337

Amended Reports Issued in 2016

Advancing the Science

Myriad is dedicated, above all else, to improving patient care through pioneering research and the development of innovative molecular diagnostic tests. Since 1991, Myriad has invested more than a billion dollars to enhance the world’s collective scientific understanding of disease through collaborative research, outreach and education and to translate that knowledge into molecular and companion diagnostic tools that save and improve the lives of the patients we serve.

Genes Icon

487

Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years

Genes Icon

$341.7 Million

Invested in research over the past 5 years

Genes Icon

57

Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.